研究单位：[1]Ministry of Science and Technology of the People´s Republic of China[2]Beijing Tiantan Hospital[3]The First Affiliated Hospital of Anhui Medical University,Hefei,Anhui,China,230022[4]The First Affiliated Hospital of Anhui University of CM,Hefei,Anhui,China,230031[5]Beijing Chao-Yang Hospital, Capital Medical University,Beijing,Beijing,China,100020[6]Beijing Fengtai You Anmen Hospital,Beijing,Beijing,China,100069[7]Beijing Tian Tan Hospital, Capital Medical University,Beijing,Beijing,China,100070[8]Dongfang Hospital Beijing University of Chinese Medicine,Beijing,Beijing,China,100078[9]Chinese PLA General Hospital,Beijing,Beijing,China,100853[10]Beijing Luhe Hospital,Capital Medical University,Beijing,Beijing,China,101149[11]Beijing ShunYi Hospital,Beijing,Beijing,China,101300[12]The First Affiliated Hospital,Sun Yat-sen University,Guangzhou,Guangdong,China,510080[13]Guangdong Provincial Hospital of Traditional Chinese Medicine,Guangzhou,Guangdong,China,510120[14]The Second Affiliated Hospital of Guangzhou Medical University,Guangzhou,Guangdong,China,510260[15]Guangdong Sanjiu Brain Hospital,Guangzhou,Guangdong,China,510510[16]Shenzhen Hospital of Southern Medical University,Shenzhen,Guangdong,China,518110[17]The Affiliated Hospital of Guizhou Medical University,Guiyang,Guizhou,China,550004[18]Henan Provincial People's Hospital,Zhengzhou,Henan,China,450003[19]Wuhan NO.1 Hospital,Wuhan,Hubei,China,430022[20]Hunan Provincial People''s Hospital,Changsha,Hunan,China,410005[21]The First People''s Hospital of Changzhou,Changzhou,Jiangsu,China,213003[22]Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School,Nanjing,Jiangsu,China,210008[23]The Second Affiliated Hospital Of NanJing Medical University,Nanjing,Jiangsu,China,210008[24]Jiangxi Provincial People''s Hospital,Nanchang,Jiangxi,China,330006[25]The First Hospital of Jilin University,Chang chun,Jilin,China,130021[26]General Hospital of The Northern Theater of The Chinese People''s Liberation Army,Shenyang,Liaoning,China,110015[27]Qilu Hospital of Shandong University,Jinan,Shandong,China,250012[28]Shandong Provincial Hospital,Jinan,Shandong,China,250021[29]LiaochengI People''s Hospital,Liaocheng,Shandong,China,252000[30]The Affiliated Hospital of Qingdao University,Qingdao,Shandong,China,266000[31]The First Affiliated Hospital of Xi''an Jiaotong University,Xi''an,Shanxi,China,710061[32]The Affiliated Hospital of Northwest University,Xian,Shanxi,China,100005[33]West China Hospital Sichuan University,Chendu,Sichuan,China,610041
Intracranial atherosclerotic disease (ICAD) is the most common cause of ischemical cerebrovascular events. The risk of stroke recurrence or death of ICAD patients remains very high. Even with aggressive medical management including dual antiplatelet therapy and strict management of risk factors, 12.2 percent of patients with 70-99 percent stenosis of intracranial artery had stroke or death during 1 year follow-up. In the real world, the 30-day risk of recurrent stroke of patients with aggressive medical management was as high as 20.2 percent. Balloon angioplasty and stent for intracranial artery have become important alternative treatments to prevent recurrent stroke for patients with severe intracranial atherosclerotic stenosis. Nevertheless, the SAMMPRIS trial has suggested intracranial stenting has higher stroke and death rate than aggressive medication with high peri-procedure complication rate. Previous nonrandomized studies have showed that stroke and death rate of angioplasty for ICAD patients with severe stenosis of intracranial artery is lower than that of aggressive medication. The primary purpose of this trial is to compare intracranial angioplasty plus aggressive medical management with aggressive medical management alone for the treatment of patients with 70-99 percent intracranial artery stenosis because of ICAD and to clarify the efficacy and safety of intracranial angioplasty through a multicenter, prospective, randomized, open-label, blinded end-point trial.
